Knight Therapeutics Inc (GUD_TSE)
GUD_TSE moved a median of 0.00% 30 minutes after news, and +0.68% by the close. How GUD_TSE actually reacts to news — the realized, point-in-time move the market made, measured across 84 labeled events over the last three years with zero look-ahead.
GUD_TSE’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 38% | 24 |
| 30-min | 0.00% | 40% | 25 |
| 60-min | +0.35% | 56% | 25 |
| to close | +0.68% | 64% | 25 |
| Middle 50% of GUD_TSE reactions | -0.51% to +0.39% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 84 |
Half of all Knight Therapeutics Inc news events land between -0.51% and +0.39% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when GUD_TSE moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to GUD_TSE's baseline. Nothing else.
Recent GUD_TSE events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Knight Therapeutics Announces Launch of TAVALISSE® in Brazil | Press release | GlobeNewswire | — | — | |
| Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil | Press release | GlobeNewswire | — | — | |
| Knight Therapeutics Enters into Exclusive Distribution Agreement with Kyowa Kirin International for Poteligeo® (Mogamulizumab) | Press release | GlobeNewswire | — | — | |
| Kyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO® (mogamulizumab) for Cutaneous T-Cell Lymphoma (CTCL) Patients Across Latin America | Press release | Business Wire | — | — | |
| Knight Therapeutics Inc. places No. 345 on The Globe and Mail’s eighth annual ranking of Canada's Top Growing Companies | Press release | GlobeNewswire | — | — | |
| Knight Therapeutics Announces Regulatory Submission of GEMTESA® in Canada | Press release | GlobeNewswire | — | — | |
| Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Colombia | Press release | GlobeNewswire | — | — | |
| Knight Therapeutics Announces Supplemental Regulatory Submission for MINJUVI® (tafasitamab) in Brazil | Press release | GlobeNewswire | — | — | |
| Knight Therapeutics Announces Launch of WYNZORA® in Canada | Press release | GlobeNewswire | — | — | |
| Knight Therapeutics Reports Second Quarter 2026 Results | Press release | GlobeNewswire | — | — | |
| Notice of Knight Therapeutics' Second Quarter 2026 Results Conference Call | Press release | GlobeNewswire | — | — | |
| Knight Therapeutics Announces Repayment of Revolving Credit Facility | Press release | GlobeNewswire | — | — | |
| Knight Announces Early Warning Filing Regarding Shares of Crescita | Press release | GlobeNewswire | — | — | |
| Knight to Present at the Jefferies 2026 Healthcare Conference in New York City | Press release | GlobeNewswire | — | — | |
| Knight Therapeutics Announces Launch of TAVALISSE® in Mexico | Press release | GlobeNewswire | — | — | |
| Knight to Present at the 2026 RBC Capital Markets Global Healthcare Conference in New York City | Press release | GlobeNewswire | — | — | |
| Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Brazil | Press release | GlobeNewswire | — | — | |
| Knight Therapeutics Reports First Quarter 2026 Results | Press release | GlobeNewswire | — | — | |
| Knight Therapeutics Inc. announces voting results from the Annual General Meeting | Press release | GlobeNewswire | — | — | |
| Notice of Knight Therapeutics' First Quarter 2026 Results Conference Call | Press release | GlobeNewswire | — | — | |
| Knight to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference | Press release | GlobeNewswire | — | — | |
| Knight Therapeutics Inc. ranks on The Globe and Mail’s second annual Canada’s Top Growing Women-Led Companies and seventh annual Women Lead Here benchmark of executive gender diversity | Press release | GlobeNewswire | — | — | |
| Knight Therapeutics Reports Fourth Quarter and Year-End 2025 Results | Press release | GlobeNewswire | — | — | |
| Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil | Press release | GlobeNewswire | — | — | |
| Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico | Press release | GlobeNewswire | — | — | |
| Notice of Knight Therapeutics' Fourth Quarter and Year End 2025 Results Conference Call | Press release | GlobeNewswire | — | — | |
| Knight Therapeutics Announces Regulatory Submission of NIKTIMVO® (Axatilimab) in Brazil | Press release | GlobeNewswire | — | — | |
| Knight Therapeutics Announces Health Canada Approval for WYNZORA® to Treat Psoriasis Vulgaris | Press release | GlobeNewswire | — | — | |
| Knight Therapeutics Reports Third Quarter 2025 Results | Press release | GlobeNewswire | — | — | |
| Knight Announces Closing of US$100 Million Revolving Credit Facility | Press release | GlobeNewswire | — | — | |
| Knight Therapeutics Announces Approval and Launch of MINJUVI® (tafasitamab) in Argentina | Press release | GlobeNewswire | — | — | |
| Knight Therapeutics Announces Launch of JORNAY PM™ in Canada | Press release | GlobeNewswire | — | — | |
| Notice of Knight Therapeutics' Third Quarter 2025 Results Conference Call | Press release | GlobeNewswire | — | — | |
| Knight Therapeutics Announces Relaunch of MYFEMBREE® in Canada | Press release | GlobeNewswire | — | — | |
| Knight Therapeutics Announces Relaunch of ORGOVYX® in Canada | Press release | GlobeNewswire | — | — | |
| Knight Therapeutics Inc. places No. 384 on The Globe and Mail's seventh annual ranking of Canada's Top Growing Companies | Press release | GlobeNewswire | — | — | |
| Knight Announces Normal Course Issuer Bid | Press release | GlobeNewswire | — | — | |
| Knight Therapeutics Reports Second Quarter 2025 Results | Press release | GlobeNewswire | — | — | |
| Knight Therapeutics Announces Regulatory Submission of CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Mexico | Press release | GlobeNewswire | — | — | |
| Knight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America | Press release | GlobeNewswire | — | — | |
| Notice of Knight Therapeutics' Second Quarter 2025 Results Conference Call | Press release | GlobeNewswire | — | — | |
| Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Brazil | Press release | GlobeNewswire | — | — | |
| Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada | Press release | GlobeNewswire | — | — | |
| Knight Closes US$50 Million Revolving Credit Facility with NBC | Press release | GlobeNewswire | — | — | |
| Knight Therapeutics Announces Closing of Previously Announced Acquisition of Paladin | Press release | GlobeNewswire | — | — | |
| Knight Therapeutics and Sumitomo Pharma enter into Exclusive Licensing Agreements to commercialize Sumitomo’s Canadian Portfolio | Press release | GlobeNewswire | — | — | |
| Knight to Present at the 2025 RBC Capital Markets Global Healthcare Conference in New York City | Press release | GlobeNewswire | — | — | |
| Knight Therapeutics Reports First Quarter 2025 Results | Press release | GlobeNewswire | — | — | |
| Knight Therapeutics Announces Relaunch of ONICIT® in Brazil and Mexico | Press release | GlobeNewswire | — | — | |
| Knight Therapeutics Inc. announces voting results from the Annual General Meeting | Press release | GlobeNewswire | — | — |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the GUD_TSE section they belong to.
Where else GUD_TSE is measured.
GUD_TSE earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| NUO THERAPEUTICS INC NEW (AURX) | 84 | 0.00% | 24% |
| Eloxx Pharmaceuticals, Inc. (ELOX) | 84 | 0.00% | 14% |
| Molecular Templates, Inc. (MTEM) | 84 | -0.48% | 39% |
| PharmaCyte Biotech, Inc. (PMCB) | 84 | 0.00% | 41% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Knight Therapeutics Inc's median reaction calculated?
Every labeled GUD_TSE news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 84 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 40% of GUD_TSE's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does GUD_TSE's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.